Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
Trial details
- Registry ID
- NCT05968430
- Drugs studied
- lorundrostat
TrialRedline tracks 6 clinical trials sponsored by Mineralys Therapeutics Inc.: 2 Phase 3, 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With HypertensionNCT05968430 | lorundrostat | Active not recruiting | 2025-12-30Actual |
| Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant HypertensionNCT06153693 | lorundrostat Dose 1, lorundrostat Dose 2 | Completed | 2024-12-10Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and HypertensionNCT06785454 | Lorundrostat | Completed | 2025-12-17Actual |
| Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With AlbuminuriaNCT06150924 | Not recorded | Completed | 2025-02-27Actual |
| A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication RegimenNCT05769608 | lorundrostat Dose 1, lorundrostat Dose 2 | Completed | 2025-01-15Actual |
| Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled HypertensionNCT05001945 | MLS-101 (Part I), MLS-101 (Part II) | Completed | 2022-09-07Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-12-22Day | LorundrostatMineralys Therapeutics Inc. · MLYS | Company-disclosed PDUFA goal dateAnnounced review target | hypertension in combination with other antihypertensive drugs | Open original sourceRead source excerptWe submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs. The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026 for lorundrostat. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2026-12-22Day | LorundrostatMineralys Therapeutics Inc. · MLYS | Company-disclosed PDUFA goal dateAnnounced review target | treatment of hypertension in combination with other antihypertensive drugs | Open original sourceRead source excerptThe U.S. Food and Drug Administration (FDA) continues its review of the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
Names as written in the registry records.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Placebo-adjusted change from baseline in automated office blood pressure (AOBP) systolic blood pressure (SBP) at Week 4 Measure: Incidence and severity of adverse events (AEs). After: Measure: Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4.
NCT05968430 · Mineralys Therapeutics Inc.
Before: Estimated. After: Actual.
Before: 1400 participants (planned). After: 1076 participants (actual).
Before: Estimated. After: Actual.
Before: Dec 2025. After: 30 Dec 2025.
NCT06785454 · Mineralys Therapeutics Inc.
Before: Estimated. After: Actual.
Before: Dec 2025. After: 17 Dec 2025.
Before: Active not recruiting. After: Completed.